Literature DB >> 14673627

[Re: Peter Blower's recent review of granisetron].

Mark Russo.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 14673627     DOI: 10.1007/s00520-003-0545-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  6 in total

Review 1.  Granisetron: relating pharmacology to clinical efficacy.

Authors:  Peter R Blower
Journal:  Support Care Cancer       Date:  2002-11-15       Impact factor: 3.603

Review 2.  5-HT3 receptor antagonists: differences and similarities.

Authors:  F Roila; E Ballatori; M Tonato; A Del Favero
Journal:  Eur J Cancer       Date:  1997-08       Impact factor: 9.162

3.  Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.

Authors:  E A Perez; P Hesketh; J Sandbach; J Reeves; S Chawla; M Markman; J Hainsworth; W Bushnell; C Friedman
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

Review 4.  The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?

Authors:  Deborah L Keefe
Journal:  Oncologist       Date:  2002

Review 5.  5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.

Authors:  R E Gregory; D S Ettinger
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

6.  Heterogeneity in systemic availability of ondansetron and granisetron following oral administration.

Authors:  B W Corrigan; B Nicholls; B Thakrar; R Lam; C Grosse; J Alianti; J L Palmer
Journal:  Drug Metab Dispos       Date:  1999-01       Impact factor: 3.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.